Eli Lilly CEO Highlights Growth Drivers for Obesity Drug Market
During an interview with CNBC, Eli Lilly CEO Dave Ricks outlined three key growth drivers in the obesity drug market: expanding Medicare coverage, strong performance of its new oral weight-loss pill Foundayo, and international expansion. These factors are expected to continue supporting the company's financial momentum as it leads a significant portion of the GLP-1 medication market for both diabetes and obesity treatments. Lilly has captured about 70% of new Medicare patients starting on GLP-1 drugs since coverage began in July, with its blockbuster injectable Zepbound dominating that segment. The company also noted growing adoption of Foundayo, which now accounts for roughly one-third of all oral prescriptions and is gaining traction week over week. The CEO's comments come as Lilly breaks ground on a $6.5 billion manufacturing facility in Houston to produce the active ingredient for Foundayo among other products.
Tickers: $LLY
Topics: Foundayo launch GLP-1 medications international expansion Medicare coverage obesity drugs